United States

Pliant Therapeutics is a clinical stage biopharmaceutical company that develops and commercializes therapies for fibrosis and related diseases. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. It is also developing two additional preclinical integrin-based programs, including an oncology program and a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies.

Google

Produktleder

Dataforsker

Pliant Therapeutics

Pliant Therapeutics Åpne stillinger

Er du klar til å løfte karrieren din? Sjekk ut disse åpne rollene hos Pliant Therapeutics.